The enbrel Market is projected to grow from USD 7.5 billion in 2025 to USD 9.0 billion by 2035, representing a CAGR of 1.9% during 2026–2035. Growth is supported by continued demand for biologic therapies used to manage autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
Rheumatoid arthritis represents the largest indication segment, reflecting the substantial global burden of this chronic autoimmune disorder. Psoriatic arthritis and ankylosing spondylitis also contribute significantly to demand as diagnosis and awareness of inflammatory diseases improve.
Subcutaneous injection is the leading administration route because it offers convenience and can support self-administration outside traditional healthcare settings. The development of user-friendly delivery systems such as auto-injectors is further improving convenience and may support treatment adherence.
North America currently represents the largest regional market, supported by established healthcare infrastructure and high demand for biologic treatments. Asia-Pacific is expected to experience significant growth as healthcare access, awareness, and investment in advanced therapies increase.
